Lexicon Pharmaceuticals, Inc. LXRX
We take great care to ensure that the data presented and summarized in this overview for LEXICON PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LXRX
View all-
Artal Group S.A. Luxembourg, N4136MShares$143 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$10.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$10 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$8.62 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.69MShares$3.87 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY3.52MShares$3.69 Million0.09% of portfolio
-
Gsa Capital Partners LLP London, X02.83MShares$2.97 Million0.19% of portfolio
-
State Street Corp Boston, MA2.61MShares$2.74 Million0.0% of portfolio
-
Cibc Private Wealth Group, LLC2.24MShares$2.35 Million0.0% of portfolio
-
Ubs Group Ag2.1MShares$2.2 Million0.0% of portfolio
Latest Institutional Activity in LXRX
Top Purchases
Top Sells
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Transactions at LXRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2025
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,810
+22.83%
|
-
|
|
May 13
2025
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,810
+15.29%
|
-
|
|
May 13
2025
|
Diane E. Sullivan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,810
+50.0%
|
-
|
|
May 13
2025
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,810
+30.18%
|
-
|
|
May 13
2025
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,810
+2.59%
|
-
|
|
May 13
2025
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,810
+11.43%
|
-
|
|
Feb 28
2025
|
Lisa De Francesco SVP, IR and Corp Comm |
SELL
Payment of exercise price or tax liability
|
Direct |
9,096
-36.87%
|
$0
$0.67 P/Share
|
|
Feb 28
2025
|
Lisa De Francesco SVP, IR and Corp Comm |
BUY
Exercise of conversion of derivative security
|
Direct |
24,673
+50.0%
|
-
|
|
Feb 28
2025
|
Craig B Granowitz SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
65,308
-35.2%
|
$0
$0.67 P/Share
|
|
Feb 28
2025
|
Craig B Granowitz SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
137,934
+26.63%
|
-
|
|
Feb 28
2025
|
Alan J Main EVP, Innov & Chem Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
43,434
-11.35%
|
$0
$0.67 P/Share
|
|
Feb 28
2025
|
Alan J Main EVP, Innov & Chem Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
126,814
+10.99%
|
-
|
|
Feb 28
2025
|
Wendy Mc Dermott SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
30,004
-19.79%
|
$0
$0.67 P/Share
|
|
Feb 28
2025
|
Wendy Mc Dermott SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
98,956
+22.79%
|
-
|
|
Feb 28
2025
|
Kristen Alexander VP, Finance and Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
17,862
-18.96%
|
$0
$0.67 P/Share
|
|
Feb 28
2025
|
Kristen Alexander VP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
46,430
+16.82%
|
-
|
|
Feb 28
2025
|
Brian T Crum SVP, General Counsel & Secr. |
SELL
Payment of exercise price or tax liability
|
Direct |
45,622
-14.89%
|
$0
$0.67 P/Share
|
|
Feb 28
2025
|
Brian T Crum SVP, General Counsel & Secr. |
BUY
Exercise of conversion of derivative security
|
Direct |
128,940
+14.06%
|
-
|
|
May 10
2024
|
Artal International S.C.A. |
BUY
Exercise of conversion of derivative security
|
Indirect |
57,546,100
+29.7%
|
-
|
|
Apr 28
2024
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+4.59%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 785K shares |
|---|
| Payment of exercise price or tax liability | 211K shares |
|---|